Pfizer, Coley Enter Into Exclusive Global License for ProMune

Pfizer Inc. and Coley Pharmaceutical Group Inc. said they have entered into an exclusive global license agreement to develop, manufacture and commercialize Coley's ProMune (CPG 7909), a toll-like receptor 9 (TLR9) agonist delivered by subcutaneous injection for the potential treatment, control and prevention of cancers in humans.

Canada NewsWire (http://www.newswire.ca/en/releases/archive/March2005/24/c8542.html)